HOST - DAPT Duration According the Bleeding Risk
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 4900 participants.
Also called NCT05631769
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 4,900 participants
- Registry
-
NCT05631769
-
- Other papers using this trial's data
- Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05631769. Randomized; single masking; primary purpose treatment. Start 2020-07-24 (actual); primary completion 2024-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- HOST - DAPT Duration According the Bleeding Risk
- Acronym
- HOST-BR
- Condition
- Coronary Artery Disease
- Condition
- Acute Myocardial Infarction
- Condition
- Stable Angina
- Intervention (Drug)
- Dual antiplatelet agent duration
- Lead sponsor
- Seoul National University Hospital
- Collaborator
- Hanyang University Seoul Hospital
Record details
- Record id
cardio:ct-nct05631769- Content hash
82b378989c204bafe73a20dda5b4e152cecdf49470139f6508f33b8afcf5e92a